MaR1治疗脂多糖诱导的小鼠急性肺损伤的应用价值研究  

Application value of MaR1 in the treatment of acute lung injury induced by lipopolysaccharide in mice

作　　者：王强[1] 林飞[1] 胡召锟 林锦源 黄冰[1] 潘灵辉[1] Wang Qiang;Lin Fei;Hu Zhaokun;Lin Jinyuan;Huang Bing;Pan Linghui(Anesthesiology Department,Guangxi Medical University Affiliated Tumor Hospiatal,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院麻醉科,南宁530021

出　　处：《广西医科大学学报》2020年第5期832-836,共5页Journal of Guangxi Medical University

基　　金：国家自然科学基金资助项目(No.81960022)。

摘　　要：目的:研究MaR1治疗脂多糖(LPS)诱导的小鼠急性肺损伤(ALI)的应用价值。方法:雄性SPF级BALB/c小鼠45只,平均随机分为对照组、LPS组、MaR1组,记录、比较3组之间支气管肺泡灌洗液(BALF)细胞计数、细胞因子和蛋白质含量、肺组织损伤评分及其免疫印迹情况。结果:与LPS组比较,MaR1组BALF中的炎症细胞数量减少伴细胞质量减轻(P<0.05);肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、白介素-6(IL-6)表达水平下降(P<0.05);肺组织损伤评分显著降低(P<0.05);MaR1组核因子核因子E-2相关因子2(Nrf2)、血红素氧合酶-1(HO-1)和醌NADH脱氢酶1(NQO1)表达水平明显增加(P<0.05)。结论:MaR1能有效抑制LPS诱导的ALI小鼠模型的炎性反应,并介导多种抗氧化酶保护肺组织免于损伤,其作用机制可能与Nrf2的激活密切相关。Objective:To study the application value of MaR1 in treatingacute lung injury(ALI)induced by lipopolysaccharide(LPS)in mice.Methods:Forty-five male SPF BALB/c mice were randomly divided into control group,LPS group,and MaR1 group.Bronchoalveolar Lavage Fluid(BALF)cell count,cytokine and protein content,lung injury score,and immunoblotting were recorded and compared among the three groups.Results:Compared with LPS group,in MaR1 group,the number of inflammatory cells and cell quality in BALF were significantlydecreased(P<0.05),the expression of tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),interleukin-6(IL-6)wereobviously reduced(P<0.05),and lung injury score was significantlydecreased(P<0.05).The expressions of nuclear factor E-2 related factor 2(Nrf2),heme oxygenase-1(HO-1),and quinone NADH dehydrogenase 1(NQO1)were significantly increased in MaR1 group(P<0.05).Conclusion:MaR1 can effectively inhibit the inflammatory response of ALI micemodel induced by LPS and mediate a variety of antioxidase to protect lung tissue from injury,and its mechanism may be closely related to the activation of Nrf2.

关 键 词：脂多糖 急性肺损伤 MaR1 支气管肺泡灌洗液 氧化应激 

分 类 号：R563.8[医药卫生—呼吸系统]